

Wengen Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3008026/publications.pdf>

Version: 2024-02-01

70
papers

1,443
citations

361413

20
h-index

377865

34
g-index

80
all docs

80
docs citations

80
times ranked

2183
citing authors

#	ARTICLE	IF	CITATIONS
1	Metformin protects against myocardial ischemia-reperfusion injury and cell pyroptosis via AMPK/NLRP3 inflammasome pathway. <i>Aging</i> , 2020, 12, 24270-24287.	3.1	149
2	The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. <i>Clinical Cardiology</i> , 2015, 38, 555-561.	1.8	141
3	Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis. <i>Cardiovascular Diabetology</i> , 2022, 21, .	6.8	73
4	Association of smoking with the risk of incident atrial fibrillation: A meta-analysis of prospective studies. <i>International Journal of Cardiology</i> , 2016, 218, 259-266.	1.7	67
5	Relation of Body Mass Index With Adverse Outcomes Among Patients With Atrial Fibrillation: A Meta-Analysis and Systematic Review. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	66
6	Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation Across BMI Categories: A Systematic Review and Meta-Analysis. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 51-60.	2.2	60
7	Fluoroquinolones increase the risk of serious arrhythmias. <i>Medicine (United States)</i> , 2017, 96, e8273.	1.0	54
8	Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs. <i>Nutrition Journal</i> , 2021, 20, 89.	3.4	53
9	Genotype-phenotype relationship in patients with arrhythmogenic right ventricular cardiomyopathy caused by desmosomal gene mutations: A systematic review and meta-analysis. <i>Scientific Reports</i> , 2017, 7, 41387.	3.3	36
10	The obesity paradox for outcomes in atrial fibrillation: Evidence from an exposure-effect analysis of prospective studies. <i>Obesity Reviews</i> , 2020, 21, e12970.	6.5	35
11	Prevalence of Atrial Fibrillation and Associated Mortality Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 720129.	2.4	34
12	Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 757087.	2.4	32
13	Meta-analysis of ATRIA versus CHA2DS2-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2017, 227, 436-442.	1.7	29
14	O-GlcNAcylation of cardiac Nav1.5 contributes to the development of arrhythmias in diabetic hearts. <i>International Journal of Cardiology</i> , 2018, 260, 74-81.	1.7	27
15	Can ventricular tachycardia non-inducibility after ablation predict reduced ventricular tachycardia recurrence and mortality in patients with non-ischemic cardiomyopathy? A meta-analysis of twenty-four observational studies. <i>International Journal of Cardiology</i> , 2016, 222, 689-695.	1.7	26
16	Resting Heart Rate and the Risk of Atrial Fibrillation. <i>International Heart Journal</i> , 2019, 60, 805-811.	1.0	26
17	Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients. <i>Stroke</i> , 2021, 52, 1225-1233.	2.0	26
18	Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 109703-109711.	1.8	24

#	ARTICLE	IF	CITATIONS
19	Sevoflurane postconditioning reduces myocardial ischemia reperfusion injury-induced necroptosis by up-regulation of OGT-mediated O-GlcNAcylated RIPK3. <i>Aging</i> , 2020, 12, 25452-25468.	3.1	23
20	Association of Physical Fitness With the Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Clinical Cardiology</i> , 2016, 39, 421-428.	1.8	22
21	Hydrogen sulfide restores sevoflurane postconditioning mediated cardioprotection in diabetic rats: Role of SIRT1/Nrf2 signaling in modulated mitochondrial dysfunction and oxidative stress. <i>Journal of Cellular Physiology</i> , 2021, 236, 5052-5068.	4.1	22
22	Brugada syndrome with SCN5A mutations exhibits more pronounced electrophysiological defects and more severe prognosis: A meta-analysis. <i>Clinical Genetics</i> , 2020, 97, 198-208.	2.0	21
23	Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney Disease or on Dialysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 273-281.	2.6	19
24	Relationship between retinal vascular occlusions and incident cerebrovascular diseases. <i>Medicine (United States)</i> , 2016, 95, e4075.	1.0	17
25	Do Implantable Cardioverter Defibrillators Reduce Mortality in Patients With Chronic Kidney Disease at All Stages?. <i>International Heart Journal</i> , 2017, 58, 371-377.	1.0	17
26	The Prevalence and Associated Death of Ventricular Arrhythmia and Sudden Cardiac Death in Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 795750.	2.4	17
27	Potential Cardiovascular Risks of Proton Pump Inhibitors in the General Population. <i>International Heart Journal</i> , 2017, 58, 163-166.	1.0	16
28	Ankyrin-B Q1283H Variant Linked to Arrhythmias Via Loss of Local Protein Phosphatase 2A Activity Causes Ryanodine Receptor Hyperphosphorylation. <i>Circulation</i> , 2018, 138, 2682-2697.	1.6	16
29	A mutation in the CACNA1C gene leads to early repolarization syndrome with incomplete penetrance: A Chinese family study. <i>PLoS ONE</i> , 2017, 12, e0177532.	2.5	15
30	Real-World Relationship Between Proton Pump Inhibitors and Cerebro-Cardiovascular Outcomes Independent of Clopidogrel. <i>International Heart Journal</i> , 2019, 60, 910-918.	1.0	15
31	Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 139-147.	2.2	15
32	Non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: evidences from the real-world data. <i>Heart Failure Reviews</i> , 2020, 25, 957-964.	3.9	15
33	Relationship between smoking and adverse outcomes in patients with atrial fibrillation: A meta-analysis and systematic review. <i>International Journal of Cardiology</i> , 2016, 222, 289-294.	1.7	14
34	Non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 311-317.	2.1	13
35	Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Peripheral Artery Disease: a Systematic Review and Meta-Analysis. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 391-399.	2.6	13
36	Influence of polypharmacy on patients with heart failure with preserved ejection fraction: a retrospective analysis on adverse outcomes in the TOPCAT trial. <i>British Journal of General Practice</i> , 2021, 71, e62-e70.	1.4	13

#	ARTICLE	IF	CITATIONS
37	C2HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial. <i>BMC Medicine</i> , 2021, 19, 44.	5.5	11
38	Effectiveness and Safety of DOACs vs. VKAs in AF Patients With Cancer: Evidence From Randomized Clinical Trials and Observational Studies. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 766377.	2.4	11
39	Association of body mass index and all-cause mortality in patients after cardiac surgery: A dose-response meta-analysis. <i>Nutrition</i> , 2020, 72, 110696.	2.4	10
40	Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	10
41	Effect of anticoagulation therapy in older patients with chronic kidney disease and atrial fibrillation. <i>Medicine (United States)</i> , 2019, 98, e17628.	1.0	9
42	Usefulness of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for predicting incident atrial fibrillation in heart failure with preserved ejection fraction patients. <i>ESC Heart Failure</i> , 2021, 8, 1369-1377.	3.1	9
43	CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 763-772.	2.6	8
44	Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 569-578.	2.6	8
45	Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 81154-81166.	1.8	7
46	Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 681726.	2.4	7
47	Sex-Specific Exposure-Effect Relationship Between Physical Activity and Incident Atrial Fibrillation in the General Population: A Dose-Response Meta-Analysis of 16 Prospective Studies. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 710071.	2.4	7
48	Variant rs2200733 and rs10033464 on chromosome 4q25 are associated with increased risk of atrial fibrillation after catheter ablation: Evidence from a meta-analysis. <i>Cardiology Journal</i> , 2018, 25, 628-638.	1.2	7
49	Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 37-47.	2.2	6
50	Living Alone and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>Psychosomatic Medicine</i> , 2021, 83, 470-476.	2.0	6
51	Major depression and clinical outcomes in patients with heart failure with preserved ejection fraction. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13401.	3.4	6
52	Genotype-based clinical manifestation and treatment of Chinese long QT syndrome patients with <i>KCNQ1</i> mutations â€“ R380S and W305L. <i>Cardiology in the Young</i> , 2016, 26, 754-763.	0.8	5
53	Association of physical activity and risk of atrial fibrillation in heart failure with preserved ejection fraction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 247-253.	2.6	5
54	Association of Body-Weight Fluctuation With Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 689591.	2.4	5

#	ARTICLE	IF	CITATIONS
55	Reappraisal of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 757188.	2.4	5
56	The "Obesity Paradox" in Patients With HFpEF With or Without Comorbid Atrial Fibrillation. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 743327.	2.4	5
57	Association of Depression, Antidepressants With Atrial Fibrillation Risk: A Systemic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	2.4	5
58	Association of long-term SBP with clinical outcomes and quality of life in heart failure with preserved ejection fraction: an analysis of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. <i>Journal of Hypertension</i> , 2021, 39, 1378-1385.	0.5	4
59	Association of body mass index and prognosis in patients with HFpEF: A dose-response meta-analysis. <i>International Journal of Cardiology</i> , 2022, 361, 40-46.	1.7	4
60	Off-label underdosing of four individual <sc>NOACs</sc> in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of observational studies. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	3.4	4
61	Dose-response relationship of cardiorespiratory fitness with incident atrial fibrillation. <i>Heart Failure Reviews</i> , 2020, 25, 419-425.	3.9	3
62	Sex-Specific Associations of Risks and Cardiac Structure and Function With Microalbumin/Creatinine Ratio in Diastolic Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 579400.	2.4	2
63	Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT. <i>ESC Heart Failure</i> , 2020, 7, 3801-3809.	3.1	2
64	Associations of BMI with mortality in HFpEF patients with concomitant diabetes with insulin versus non-insulin treatment. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109805.	2.8	2
65	Associations of Antidepressants With Atrial Fibrillation and Ventricular Arrhythmias: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 840452.	2.4	2
66	Impact of COPD or Asthma on the Risk of Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 872446.	2.4	2
67	GW27-e0836 Association of smoking with the risk of incident atrial fibrillation: a meta-analysis of prospective studies. <i>Journal of the American College of Cardiology</i> , 2016, 68, C75-C76.	2.8	1
68	Role of Second-Generation Drug-Eluting Stents and Bypass Grafting in Coronary Artery Disease: A Systematic Review and Meta-analysis. <i>Cardiovascular Innovations and Applications</i> , 2017, 2, .	0.3	0
69	Author's Reply to Vaz et al.: "Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease". <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 507-508.	2.2	0
70	Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four post-hoc Analyses of Randomized Clinical Trials. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 841341.	2.4	0